GAP, initiated by the New York Academy of Sciences and Global CEO Initiative, is moving one step closer to reaching its goal of establishing a global, trial-ready platform for Alzheimer’s disease.
The Global Alzheimer’s Platform (GAP) and the Innovative Medicines Initiative (IMI) announced today that they will sign a Memorandum of Understanding (MOU) to accelerate Alzheimer’s drug development by building a global, standing, trial-ready platform for Alzheimer’s drug development.
The collaboration represents a significant commitment to work together to recruit patients for clinical trials, to create a high-performing clinical trial system, and to develop a standing adaptive protocol to test new molecules quickly, and move those with promise into later stage development.
Source: New York Academy of Sciences